Search Results

Bortezomib

Bortezomib is FDA approved to treat people with myeloma and for the retreatment of adult patients with myeloma who had previously responded to bortezomib therapy and relapsed at least six months following completion of prior bortezomib treatment. Bortezomib is also approved to treat people with previously untreated mantle cell lymphoma as well as patients who have received at least one prior therapy.

Avoiding Roadblocks in Coordinating CAR-T Therapy for B-cell Lymphoma: Practical Tips for Community Oncology Clinicians

NEW SURVEY FROM THE LEUKEMIA & LYMPHOMA SOCIETY REVEALS LOW AWARENESS ABOUT BLOOD CANCERS

The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

PRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute Leukemia

The Leukemia & Lymphoma Society 2025 Research Grants Include Acute Leukemia in Children with Down Syndrome

The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

Leading Treatment for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Now Available in Tablet Form

Alice, myeloma survivor, on a hiking trip, standing in front of mountains

Myeloma Awareness Month: Aiming for more

Helping Blood Cancer Patients and Families When It's Needed Most

In honor of Blood Cancer Awareness Month, Dr. Gwen Nichols reflects on our vital work to support blood cancer patients and their families.

Announcing a New Light The Night T-shirt Contest Winner, Drumroll Please…

The Leukemia & Lymphoma Society (LLS) has officially tallied up the votes for the 2016 Light The Night t-shirt contest submissions, and the winning design comes from 37-year-old Joshua Redmond of Centerville, Ohio.

A graduate of Ohio University’s School of Fine Art, Redmond earned his degree in graphic design and printmaking and has been working professionally in the industry for over a decade.

Stock image of woman with hands on chest, breathing, in front of sunset

Exercise for blood cancer patients

Table of contents:

A phase 1 study of VIPER-101, a CD5-edited dual population chimeric antigen receptor cell therapy, to enhance immunotherapy against T-cell non-Hodgkin lymphoma

In October 2023, LLS made an equity investment in Vittoria to "Support Clinical Development of VIPER-101, a CAR-T Cell Therapy for T-cell lymphomas."

It's Time To Understand CAR-T Therapy For B-Cell Lymphoma: Earlier Indications Coming To A Community Near You

Episode for Social Workers: Avoiding Roadblocks in Getting Your B-Cell Lymphoma Patients to CAR T-CELL Therapy

BioInvent Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Receives $3 Million Strategic Equity Investment

Faron Announces Results of Placing, Including Additional Investment by The Leukemia & Lymphoma Society Therapy Acceleration Program®

World Renowned Childhood Blood Cancer Expert Named as The Leukemia & Lymphoma Society's New President and CEO

The Leukemia & Lymphoma Society (LLS) Announces Board of Directors Officer Appointments; Welcomes New Board Member

Francie Heller, Managing Partner at Heller Advisory, Elected to The Leukemia & Lymphoma Society National Board of Directors

Immunotherapy Study Funded by The Leukemia & Lymphoma Society Demonstrates Remarkable Results in Patients with Acute Lymphoblastic Leukemia

Genomics of Diffuse Large B Cell Lymphoma: pervasive role of super-enhancer hypermutation in dysregulating oncogene expression

We recently identified a pervasive, pathogenically relevant mutational mechanism that targets super-enhancers (SE) in DLBCL, leading to target gene deregulation. Here we will dissect the mechanistic role of 3 highly recurrent hotspots in the BCL6, BTG2 and CXCR4 SEs in driving lymphomagenesis and tumor dependency in vitro and in vivo using novel mouse models. These studies will significantly transform our understanding of DLBCL and identify novel therapeutic targets.